IRIS
SIGNORIELLO, Elisabetta
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.201
AS - Asia 1.606
NA - Nord America 1.422
SA - Sud America 357
AF - Africa 25
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 1
Totale 5.616
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.386
RU - Federazione Russa 1.038
SG - Singapore 596
IE - Irlanda 405
CN - Cina 392
BR - Brasile 311
HK - Hong Kong 291
IT - Italia 220
DE - Germania 153
GB - Regno Unito 146
KR - Corea 103
VN - Vietnam 94
UA - Ucraina 47
IN - India 45
FR - Francia 37
GR - Grecia 31
JP - Giappone 28
FI - Finlandia 27
AR - Argentina 24
MX - Messico 21
SE - Svezia 17
TR - Turchia 13
AT - Austria 12
CA - Canada 11
PL - Polonia 11
BE - Belgio 10
NL - Olanda 10
CZ - Repubblica Ceca 9
EC - Ecuador 8
ID - Indonesia 8
HU - Ungheria 6
PK - Pakistan 6
TN - Tunisia 6
ES - Italia 5
IL - Israele 5
IQ - Iraq 5
BD - Bangladesh 4
CO - Colombia 4
LT - Lituania 4
MA - Marocco 4
ZA - Sudafrica 4
AZ - Azerbaigian 3
BO - Bolivia 3
CH - Svizzera 3
EG - Egitto 3
PY - Paraguay 3
SA - Arabia Saudita 3
AU - Australia 2
BY - Bielorussia 2
ET - Etiopia 2
JO - Giordania 2
KE - Kenya 2
NZ - Nuova Zelanda 2
PE - Perù 2
PT - Portogallo 2
RS - Serbia 2
UZ - Uzbekistan 2
VE - Venezuela 2
AE - Emirati Arabi Uniti 1
AO - Angola 1
BG - Bulgaria 1
CG - Congo 1
CR - Costa Rica 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
IR - Iran 1
IS - Islanda 1
JM - Giamaica 1
KG - Kirghizistan 1
KZ - Kazakistan 1
MD - Moldavia 1
NG - Nigeria 1
NP - Nepal 1
PA - Panama 1
PH - Filippine 1
SN - Senegal 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 5.616
Salva come PNG Salva come JPEG
Città #
Dublin 403
Moscow 320
Hong Kong 291
Santa Clara 291
Singapore 223
Chandler 148
Seoul 103
Hefei 87
Dallas 84
Jacksonville 79
Beijing 64
Munich 55
Princeton 53
Roxbury 53
Bremen 46
Caserta 42
Ho Chi Minh City 39
New York 38
The Dalles 36
Ashburn 34
Naples 34
Ann Arbor 32
Bengaluru 32
Cambridge 30
Medford 30
Redhill 26
São Paulo 26
Los Angeles 23
Boardman 18
Hanoi 17
Wilmington 16
Des Moines 13
Milan 13
Aversa 12
Norwalk 12
Rio de Janeiro 12
Nuremberg 11
Brussels 10
Turku 10
Falkenstein 9
Helsinki 9
Warsaw 8
Mexico City 7
Nanjing 7
San Francisco 7
Belo Horizonte 6
Boston 6
Redwood City 6
Rome 6
San Mateo 6
Tianjin 6
Brasília 5
Jinan 5
Mountain View 5
Salto 5
Toronto 5
Vienna 5
Brooklyn 4
Cercola 4
Curitiba 4
Guangzhou 4
Guarulhos 4
Houston 4
Hyderabad 4
Marcianise 4
Nanchang 4
Quito 4
San Giorgio A Cremano 4
Santa Maria 4
Seattle 4
Stockholm 4
Thái Bình 4
Woodbridge 4
Amsterdam 3
Ankara 3
Atibaia 3
Atlanta 3
Baku 3
Bari 3
Bauru 3
Belém 3
Biên Hòa 3
Brno 3
Campinas 3
Campo Grande 3
Casablanca 3
Chicago 3
Darmstadt 3
Harbin 3
Jakarta 3
Lappeenranta 3
Napoli 3
Ottawa 3
Pavia 3
Philadelphia 3
Phoenix 3
Prague 3
São José dos Pinhais 3
Tunis 3
Wroclaw 3
Totale 3.124
Salva come PNG Salva come JPEG
Nome #
Epstein Barr virus infection reactivation as a possible trigger of primary biliary cirrhosis-like syndrome in a patient with multiple sclerosis in the course of fingolimod treatment. 122
Adiponectin profile at baseline is correlated to progression and severity of multiple sclerosis 115
Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies 109
12-months prospective Pentraxin-3 and metabolomic evaluation in multiple sclerosis patients treated with glatiramer acetate 109
Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis 107
Alemtuzumab significantly improves posterior fossa syndrome presented as a relapse of multiple sclerosis 101
Is the pathology of posterior cortical atrophy clinically predictable? 99
Associations between cognitive impairment at onset and disability accrual in young people with multiple sclerosis 99
Lymphocytosis as a response biomarker of natalizumab therapeutic efficacy in multiple sclerosis 98
Cost-Effectiveness Analysis of Cannabinoid Oromucosal Spray Use for the Management of Spasticity in Subjects with Multiple Sclerosis 98
Diagnostic contribution of magnetic resonance imaging in an atypical presentation of motor neuron disease 97
Preliminary results of the FASM study, an on-going italian active pharmacovigilance project 95
Assessing association of comorbidities with treatment choice and persistence in MS: A real-life multicenter study. 92
Adiponectin in Cerebrospinal Fluid from Patients Affected by Multiple Sclerosis Is Correlated with the Progression and Severity of Disease 92
Clinical activity after fingolimod cessation: disease reactivation or rebound? 90
Rare Variants in Autophagy and Non-Autophagy Genes in Late-Onset Pompe Disease: Suggestions of Their Disease-Modifying Role in Two Italian Families 89
Fingolimod efficacy in multiple sclerosis associated with Sjogren syndrome 88
BMI influences CD20 kinetics in multiple sclerosis patients treated with ocrelizumab 87
Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study 87
Alemtuzumab-Related Lymphocyte Subset Dynamics and Disease Activity or Autoimmune Adverse Events: Real-World Evidence 85
Apparently isolated CNS involvement in Erdheim-Chester disease: Case report 85
Predictors of Cladribine Effectiveness and Safety in Multiple Sclerosis: A Real-World, Multicenter, 2-Year Follow-Up Study 84
Assessment of Multiple Sclerosis Disability Progression Using a Wearable Biosensor: A Pilot Study 84
Disability assessment using Google Maps 84
Influence of Previous Disease-Modifying Drug Exposure on T-Lymphocyte Dynamic in Patients With Multiple Sclerosis Treated With Ocrelizumab 84
Cladribine vs other drugs in MS: Merging randomized trial with real-life data 82
Cd19 cell count at baseline predicts b cell repopulation at 6 and 12 months in multiple sclerosis patients treated with ocrelizumab 82
Multiple sclerosis and genetic polymorphisms in fibrinogen-mediated hemostatic pathways: a case–control study 82
Migraine as possible red flag of PFO presence in suspected demyelinating disease 81
Clinical predictors of Dimethyl Fumarate response in multiple sclerosis: a real life multicentre study 81
Treatment withdrawal in relapsing-remitting multiple sclerosis: a retrospective cohort study 80
Correction to: Adiponectin in Cerebrospinal Fluid from Patients Affected by Multiple Sclerosis Is Correlated with the Progression and Severity of Disease 80
Systematic Review on the Role of Lobar Cerebral Microbleeds in Cognition 80
The EDSS integration with the Brief International Cognitive Assessment for Multiple Sclerosis and orientation tests 78
A snapshot on patient-reported outcome measures of people with multiple sclerosis on first-line therapies in a real world setting 77
A real-world study of alemtuzumab in a cohort of Italian patients 77
Health related quality of life in the domain of physical activity predicts confirmed disability progression in people with relapsing remitting multiple sclerosis 75
The effect of air pollution on COVID-19 severity in a sample of patients with multiple sclerosis 75
Treatment of multiple sclerosis with rituximab: A multicentric Italian-Swiss experience 75
Is It Time for Ocrelizumab Extended Interval Dosing in Relapsing Remitting MS? Evidence from An Italian Multicenter Experience During the COVID-19 Pandemic 74
Signs and symptoms of COVID-19 in patients with multiple sclerosis 73
Determinants of therapy switch in multiple sclerosis treatment-naïve patients: A real-life study 73
COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patients 69
Exposure to natalizumab throughout pregnancy: effectiveness and safety in an Italian cohort of women with multiple sclerosis 67
Diffuse glioblastoma resembling acute hemorrhagic leukoencephalitis 67
Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study) 66
Short and long term effects of Nabiximols on balance and walking assessed by 3D-gait analysis in people with Multiple Sclerosis and spasticity 66
Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy 66
Is antibody titer useful to verify the immunization after VZV Vaccine in MS patients treated with Fingolimod? A case series 64
MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study 62
Whole-brain propagation delays in multiple sclerosis, a combined tractography - magnetoencephalography study 60
Role of Ocrelizumab in modulating gene and microRNA expression in multiple sclerosis 57
Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved? 57
Healthcare resource utilization and costs for multiple sclerosis management in the Campania region of Italy: Comparison between centre-based and local service healthcare delivery. 57
Integrated cognitive and neuromotor rehabilitation in multiple sclerosis: A pragmatic study 56
Palatability and oral cavity tolerability of THC:CBD oromucosal spray and possible improvement measures in multiple sclerosis patients with resistant spasticity: a pilot study 56
Adiponectin Alleviates Cell Injury due to Cerebrospinal Fluid from Multiple Sclerosis Patients by Inhibiting Oxidative Stress and Proinflammatory Response 56
Fingolimod reduces the clinical expression of active demyelinating lesions in MS 54
Switch from sequestering to anti-CD20 depleting treatment: disease activity outcomes during wash-out and in the first 6 months of ocrelizumab therapy 54
Prognostic Markers of Ocrelizumab Effectiveness in Multiple Sclerosis: A Real World Observational Multicenter Study 54
Nociplastic Pain in Multiple Sclerosis Spasticity: Dermatomal Evaluation, Treatment with Intradermal Saline Injection and Outcomes Assessed by 3D Gait Analysis: Review and a Case Report 54
Impact of Lifestyle Interventions on Multiple Sclerosis: Focus on Adipose Tissue 53
Ocrelizumab and ofatumumab comparison: an Italian real-world propensity score matched study 52
Maternal and fetal outcomes in an Italian multicentric cohort of women with multiple sclerosis exposed to dimethyl fumarate during pregnancy 51
Lifestyle and Mediterranean diet adherence in a cohort of Southern Italian patients with Multiple Sclerosis 51
Unraveling diagnostic uncertainty in transition phase from relapsing-remitting to secondary progressive multiple sclerosis 50
Ocrelizumab in a case of refractory Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) with antibodies anti Rituximab 48
Exploring Circulating Long Non-Coding RNAs in Mild Cognitive Impairment Patients' Blood 48
Ocrelizumab Alters Cytotoxic Lymphocyte Function While Reducing EBV-Specific CD8 + T-Cell Proliferation in Patients With Multiple Sclerosis 47
Real-world comparison of lymphopenia profiles in S1P receptor modulators for multiple sclerosis: a multicenter retrospective study 47
Impact of COVID-19 on pregnancy and fetal outcomes in women with multiple sclerosis 47
Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis 46
Validation of an iPad version of the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) 45
Effects of THC/CBD oromucosal spray on spasticity-related symptoms in people with multiple sclerosis: results from a retrospective multicenter study 45
Italian Alemtuzumab Study Group. No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study. 45
Outcomes after fingolimod to alemtuzumab treatment shift in relapsing–remitting MS patients: a multicentre cohort study 44
NEDA-3 achievement in early highly active relapsing remitting multiple sclerosis patients treated with Ocrelizumab or Natalizumab 42
Therapeutic choices and disease activity after 2 years of treatment with cladribine: An Italian multicenter study (CladStop) 41
First therapy choice in newly diagnosed Multiple Sclerosis patients: A multicenter Italian study 38
MicroRNA-142-3p shuttling in extracellular vesicles marks regulatory T cell dysfunction in multiple sclerosis 36
Long-Term Effectiveness and Safety of Rituximab in Neuromyelitis Optica Spectrum Disorder: A 5-Year Observational Study 34
Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies 33
Identifying Cladribine prescription pattern in MS: an Italian multicentre study 32
Totale 5.822
Salva come PNG Salva come JPEG
Categoria #
all - tutte 24.643
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 24.643
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021122 0 0 0 0 0 1 34 13 9 21 33 11
2021/2022422 13 38 3 12 99 7 10 8 30 50 25 127
2022/2023701 72 18 9 45 79 42 0 35 353 6 23 19
2023/2024376 23 11 22 21 107 41 33 5 8 3 24 78
2024/20251.432 2 22 8 47 210 194 150 125 228 208 136 102
2025/20262.390 193 291 356 281 498 771 0 0 0 0 0 0
Totale 5.822